Publications

2017

Research articles

RNA expression profiling reveal differentially regulated growth factor and receptor expression in redirected cancer cells.
Schmucker HS, Park JP, Coissieux MM, Bentires-Alj M, Feltus FA, Booth B.
Stem Cells Dev. 2017 Jan 23. doi: 10.1089/scd.2016.0340.

The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ERα.
Britschgi A, Duss S, Kim S, Couto JP, Brinkhaus H, Koren S, De Silva D, Mertz KD, Kaup D, Varga Z, Voshol H, Vissieres A, Leroy C, Roloff T, Stadler MB, Scheel CH, Miraglia LJ, Orth AP, Bonamy GM, Reddy VA, Bentires-Alj M.
Nature. 2017 Jan 26;541(7638):541-545. doi: 10.1038/nature20829. Epub 2017 Jan 9.

2016

Research articles

Serpin E2 promotes breast cancer metastasis by remodeling the tumor matrix and polarizing tumor associated macrophages.
Smirnova T, Bonapace L, MacDonald G, Kondo S, Wyckoff J, Ebersbach H, Fayard B, Doelemeyer A, Coissieux MM, Heideman MR, Bentires-Alj M, Hynes NE.
Oncotarget. 2016 Dec 13;7(50):82289-82304. doi: 10.18632/oncotarget.12927.

Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition.
Leroy C, Ramos P, Cornille K, Bonenfant D, Fritsch C, Voshol H, Bentires-Alj M.
Breast Cancer Res. 2016 Apr 5;18(1):41. doi: 10.1186/s13058-016-0697-1.

Reviews and commentaries

Patient-derived xenograft (PDX) models in basic and translational breast cancer research.
Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT.
Cancer Metastasis Rev. 2016 Dec;35(4):547-573. doi: 10.1007/s10555-016-9653-x.

Complexity galore: 3D cultures, biomechanics and systems medicine at the eighth ENBDC workshop “Methods in Mammary Gland Development and Cancer”.
Lloyd-Lewis B, van de Moosdijk AA, Bentires-Alj M, Clarke RB, van Amerongen R.
Breast Cancer Res. 2016 Nov 25;18(1):115.

2015

Research articles

CUB-domain-containing protein 1 overexpression in solid cancers promotes cancer cell growth by activating Src family kinases.
Leroy C, Shen Q, Strande V, Meyer R, McLaughlin ME, Lezan E, Bentires-Alj M, Voshol H, Bonenfant D, Alex Gaither L.
Oncogene. 2015 Oct 29;34(44):5593-8. doi: 10.1038/onc.2015.19. Epub 2015 Mar 2.

Sausgruber N, Coissieux MM, Britschgi A, Wyckoff J, Aceto N, Leroy C, Voshol H, Bonenfant D, Bentires-Alj M

Tyrosine phosphatase SHP2 increases cell motility in triple negative breast cancer via activation of SRC family kinases.
Oncogene. 2015 Apr 23;34(17):2272-8. doi: 10.1038/onc.2014.170. Epub 2014 Jun 16

Reviews and commentaries

Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy.
Koren S, Bentires-Alj M.
Mol Cell. 2015 Nov 19;60(4):537-46. doi: 10.1016/j.molcel.2015.10.031. Review.

The seventh ENBDC workshop on methods in mammary gland development and cancer.
Glukhova MA, Hynes N, Vivanco Md, van Amerongen R, Clarke RB, Bentires-Alj M.
Breast Cancer Res. 2015 Sep 2;17(1):119. doi: 10.1186/s13058-015-0629-5.

Stimulating translational research: several European life science institutions put their heads together.
Bentires-Alj M, Rajan A, van Harten W, van Luenen HG, Kubicek S, Andersen JB, Saarela J, Cook SJ, Van Minnebruggen G, Roman-Roman S, Maurer C, Erler JT, Bertero MG.
Trends Mol Med. 2015 Sep;21(9):525-7. doi: 10.1016/j.molmed.2015.07.002. Epub 2015 Aug 5.

Breast cancer prevention: lessons to be learned from mechanisms of early pregnancy-mediated breast cancer protection.
Meier-Abt F, Bentires-Alj M, Rochlitz C.
Cancer Res. 2015 Mar 1;75(5):803-7. doi: 10.1158/0008-5472.CAN-14-2717. Epub 2015 Feb 6.

Mechanism-based cancer therapy: resistance to therapy, therapy for resistance.
Ramos P, Bentires-Alj M.
Oncogene. 2015 Jul;34(28):3617-26. doi: 10.1038/onc.2014.314. Epub 2014 Sep 29. Review.

 

2014

Research articles

Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis.
Bonapace L, Coissieux MM, Wyckoff J, Mertz KD, Varga Z, Junt T, Bentires-Alj M.
Nature. 2014 Nov 6;515(7525):130-3. doi: 10.1038/nature13862. Epub 2014 Oct 22.

Duss S, Brinkhaus H, Britschgi A, Frey D, Schaefer D, Ringenbach P, Thiebault S, Lindner V, Bentires-Alj M
Heterotypic ex vivo culture maintains the differentiation potential of human breast epithelial and mesenchymal precursors
Breast Cancer Research, 10;16(3):R60. (2014)

Early but not late pregnancy induces a life-long reduction in mammary hormone responsiveness and epithelial Wnt signaling
Meier-Abt F, Brinkhaus H and Bentires-Alj M
Breast Cancer Research, 16:402 (2014)

Meyer DS, Aceto N, Sausgruber N, Brinkhaus H, Müller U, Pallen CJ, Bentires-Alj M
Tyrosine Phosphatase PTPα Contributes to HER2-Evoked Breast Tumor Maintenance but is Dispensable for tumor Initiation.
Oncogene, 16; 33(3): 398-402 (2014)

MacDonald G, Nalvarte I¶, Smirnova T, Vecchi M, Aceto N, Dolemeyer A, Frei A, Lienhard S, Wyckoff J, Hess D, Seebacher J, Keusch JJ, Gut H, Salaun D, Mazzaro G, Disalvatore D, Bentires-Alj M, Di Fiore PP, Badache A, Hynes NE
Memo is a Copper-Dependent Redox Protein with an Essential Role in Migration and Metastasis.
Science Signaling, 7(329):ra56 (2014)

Fantozzi A, Gruber DC, Pisarsky L, Heck C, Kunita A, Yilmaz M, Meyer-Schaller N, Cornille K, Hopfer U, Bentires-Alj M, Christofori G
VEGF-mediated angiogenesis links EMT-induced cancer stemness to tumor initiation
Cancer Research. 74(5):1566-75 (2014)

Shostak K, Patrascu F, Göktuna SI, Rammal A, Close P, Nguyen L, Olivier F, Hochepied T, Haigh JJ, Libert C, Brinkhaus H, Bentires-Alj M, Marine JC, Chariot A
MDM2 restrains estrogen-mediated AKT activation by promoting TBK1-dependent HPIP degradation.
Cell Death Diff., 21(5):811-24 (2014)

Reviews and commentaries

Anticipating mechanisms of resistance to PI3K inhibition in breast cancer: a challenge in the era of precision medicine.
Leroy C, Amante RJ, Bentires-Alj M.
Biochem Soc Trans. 2014 Aug;42(4):733-41. doi: 10.1042/BST20140034. Review.

Meier-Abt F and Bentires-Alj M
How pregnancy at early age protects against breast cancer
Trends in Molecular Medicine, 20(3):143-53 (2014)
(Cover of the journal)

2013

Research articles

Meyer DS, Koren S, Leroy C, Brinkhaus H, Müller U, Müller M, Cardiff RD, Bentires-Alj M
Expression of PIK3CA Mutant E545K in the Mammary Gland Induces Heterogeneous Tumors but is Less Potent than Mutant H1047R
Oncogenesis, Sep 30;2:e74 (2013).

Alajati A, Sausgruber N, Aceto N, Duss S, Sarret S, Voshol H, Bonenfant D, Bentires-Alj M
Mammary tumor formation and metastasis evoked by a HER2 splice variant
Cancer Research, 73(17):5320-7 (2013).

Meier-Abt F, Roloff T, Brinkhaus H, Milani E, Duss S, Klebba I, Balwierz P, van Nimwegen E, Bentires-Alj M
Parity Induces Differentiation and Reduces Proliferation Potential and Wnt/Notch Signaling Ratio in Mouse Mammary Stem Cells.
Breast Cancer Research, 15(2): R36 (2013).
(Commentary by D. Medina, BCR 2013)

Britschgi A*, Bill A*, Brinkhaus H, Rothwell C, Clay I, Duss S, Rebhan M, Raman P, Guy C, Wetzel K, George E, Oana Popa M, Lilley S, Choudhury H, Gosling M, Wang L, Fitzgerald S, Borawski J, Baffoe J, Labow M, Gaither LA**, Bentires-Alj M**
The calcium activated chloride channel ANO1 promotes breast cancer progression by activating EGFR- and CAMK-signaling.
PNAS plus, 110 (11) 1026-34 (2013).
(Research Highlights, Nature Reviews Cancer 2013)

Milani ES, Brinkhaus H, Dueggeli R, Klebba I, Mueller U, Stadler M, Kohler H, Smalley MJ, Bentires-Alj M
Protein Tyrosine Phosphatase 1B Restrains Mammary Alveologenesis and Secretory Differentiation
Development, 140(1):117-25 (2013)

Blache U, Silván U, Plodinec M, Suetterlin R, Jakob R, Klebba I, Bentires-Alj M, Aebi U, and Schoenenberger CA
A tumorigenic actin mutant alters fibroblast morphology and multicellular assembly properties
Cytoskeleton, 70(10):635-50 (2013)

Reviews and commentaries

Britschgi A, Radimerski T, Bentires-Alj M
Targeting PI3K, HER2 and the IL-8/JAK2 axis in metastatic breast cancer: with which combination is the whole greater than the sum of its parts?
Drug Resistance Updates, 16(3-5):68-72 (2013)

Clarke R, Stingl J, Vivanco M, Bentires-Alj M
“The charmingest place”: Non-coding RNA, lineage tracing, tumour heterogeneity, metastasis and metabolism – new methods in mammary gland development and cancer.
Breast Cancer Research, 15(5):313 (2013)

Koren S and Bentires-Alj M
Mouse Models of PIK3CA Mutations: One Mutation Initiates Heterogeneous Mammary Tumors
FEBS J, 280(12):2758-65 (2013)

2012

Research articles

Britschgi A, Andraos R, Brinkhaus H, Klebba I, Romanet V, Müller U, Murakami M, Radimerski T, Bentires-Alj M
JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade, Providing a Rationale for Co-targeting these Pathways in Metastatic Breast Cancer.
Cancer Cell, 22(6):796-811 (2012)
(Featured by R. Abraham in Cancer Cell 2012) (Highlighted: Cancer Discovery 2012) (Featured by G. Wulf in BCR 2013)

Aceto N, Duss S, Macdonald G, Meyer DS, Roloff TC, Hynes NE, Bentires-Alj M
Co-expression of HER2 and HER3 receptor tyrosine kinases enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion.
Breast Cancer Research, 14(5):R131 (2012).

Aceto N, Sausgruber N, Brinkhaus H, Gaidatzis D, Martiny-Baron G, Mazzarol G, Confalonieri S, Hu G, Balwierz P, Pachkov M, Elledge SJ, van Nimwegen E, Stadler MB, Bentires-Alj M
Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop.
Nature Medicine, 18(4): 529-37 (2012)
(Featured by R. Daly in BCR)

Plodinec M, Loparic M, Monnier CA, Obermann EC, Zanetti-Dallenbach R, Oertle P, Hyotyla JT, Aebi U, Bentires-Alj M, Lim RY, Schoenenberger CA.
The nanomechanical signature of breast cancer.
Nature Nanotechnology, 7(11):757-65 (2012)
(Cover of the journal)

Hofmann I, Weiss A, Elain G, Schwaederle M, Sterker D, Romanet V, Schmelzle T, Lai A, Brachmann SM, Bentires-Alj M, Roberts TM, Sellers WR, Hofmann F, Maira SM.
K-RAS Mutant Pancreatic Tumors Show Higher Sensitivity to MEK than to PI3K Inhibition In Vivo.
PLoS One.7(8): (2012)

Reviews and commentaries

Duss S, Britschgi A, Bentires-Alj M
Hippo inactivation feeds tumor-initiating cells.
Breast Cancer Research 14(4): 318 (2012)

Bentires-Alj M, Glukhova M, Hynes N, Vivanco M
New methods in mammary gland development and cancer: proteomics, epigenetics, symmetric division and metastasis
Breast Cancer Research 14(4): 314 (2012)

Bentires-Alj M and Wood, T
Critical questions in mammary gland development, lactational biology and breast cancer.
Journal of Mammary Gland Biology and Neoplasia, 17(2) (2012)

Aceto N, Bentires-Alj M
Targeting protein-tyrosine phosphatases in breast cancer.
Oncotarget, 3(5), (2012)

Bonapace L, Wyckoff J, Oertner T, Van Rheenen J, Junt T, and Bentires-Alj M
If you don’t look, you won’t see: Intravital multiphoton imaging of primary and metastatic breast cancer.
Journal of Mammary Gland Biology and Neoplasia, 17(2): 125-129 (2012)
(Cover of the journal)

2011

Research articles

Meyer D, Brinkhaus H, Muller U, Muller M, Cardiff RD, Bentires-Alj M
Luminal expression of mutant PIK3CA in the Mammary Gland Induces Heterogeneous Tumors.
Cancer Research 71(13):4344-51 (2011)
(Featured by T. Miller in BCR)

Balavenkatraman KK, Aceto N, Britschgi A, Mueller U, Bence K, Neel BG, Bentires-Alj M
Epithelial Protein-Tyrosine Phosphatase 1B (PTP1B) Contributes to the Induction of Mammary Tumors by HER2/Neu but is not Essential for Tumor Maintenance.
Molecular Cancer Res., 9(10):1377-84 (2011)
(Highlight: Molecular Cancer Res.)

Sun T, Aceto N, Meerbrey KL, Kessler JD, Zhou C, Migliaccio I, Nguyen DX, Pavlova NN, Botero M, Huang J, Bernardi RJ, Schmitt E, Hu G, Li MZ, Dephoure N, Gygi SP, Rao M, Creighton CJ, Hilsenbeck SG, Shaw C, Muzny D, Gibbs RA, Wheeler DA, Osborne CK, Schiff R, Bentires-Alj M *, Elledge SJ *, Westbrook TF
Activation of Multiple Proto-oncogenic Tyrosine Kinases in Breast Cancer via Loss of the PTPN12 Phosphatase.
Cell 144(5), 703-18 (2011)
(Featured by J. Brugge in Cell 2011)

Agouni A, Mody N, Owen C, Czopek A, Zimmer D, Bentires-Alj M, Bence K, Delibegović M
Liver-specific deletion of PTP1B improves obesity- and pharmacologically-induced ER stress and reduces high-fat diet induced oxidative and nitrosative stress.
Biochem J. 438(2):369-78 (2011)

Reviews and commentaries

Vivanco dm M, Stingl J, Clarke R, Bentires-Alj M
The devil is in the methods: lineage tracing, functional screen and sequencing, hormones, tumor-stroma interactions, and expansion of human breast tumors as xenografts.
Breast Cancer Research, 13(5):316 (2011)

Aceto N, Bentires-Alj M
On the Road to Combinations of Targeted Therapies: PPM1H Phosphatase as a Suppressor of Trastuzumab Resistance.
Cancer Discovery. 1(4): 285-286 (2011)

2010

Research articles

Stewart RA, Sanda T, Widlund HR, Zhu S, Swanson KD, Hurley AD, Bentires-Alj M, Fisher DE, Kontaridis MI, Look AT, and Neel BG.
Phosphatase-Dependent and -Independent Functions of Shp2 in Neural Crest Cells Underlie LEOPARD Syndrome Pathogenesis.
Dev Cell 18(5): 750-762 (2010)

Reviews and commentaries

Stingl J, Smalley M, Glukhova M, Bentires-Alj M
Methods in Mammary Gland Development and cancer: The Second ENDBC Meeting – Intravital Imaging, Genomics, Modeling and Metastasis.
Breast Cancer Research 12(5):311 (2010)

Meyer DS, Bentires-Alj M
Can phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibition ERase them all?
Breast Cancer Research 12(5):315 (2010)

2009

Reviews and commentaries

Bentires-Alj M, Clarke, RB, Jonkers, J, Smalley, M, Stein, T
It’s all in the details: methods in breast development and cancer.
Breast Cancer Research, 11(4):305 (2009)

2008

Research articles

Gelsi-Boyer V, Trouplin V, Adélaïde J, Aceto N, Remy V, Pinson S, Houdayer C, Arnoulet C, Sainty D, Bentires-Alj M, Olschwang S, Vey N, Mozziconacci MJ, Birnbaum D, Chaffanet M.
Genome profiling of chronic myelomonocyticResearch articles:: frequent alterations of RAS and RUNX1 genes.
BMC Cancer. 16;8:299 (2008)

Swanson KD, Winter JM, Reis M, Bentires-Alj M, Greulich H, Grewal R, Hruban RH, Yeo CJ, Yassin Y, Iartchouk O, Montgomery K, Whitman SP, Caligiuri MA, Loh ML, Gilliland DG, Look AT, Kucherlapati R, Kern SE, Meyerson M, Neel BG.
SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients.
Genes Chromosomes Cancer. 47(3):253-9 (2008)

2007

Research articles:

Bentires-Alj M., and Neel BG.
Protein-Tyrosine Phosphatase 1B Is Required for HER2/Neu-Induced Breast Cancer.
Cancer Res. 67, 2420-4 (2007)
(Highlight: Cancer Res) (Featured by N. Tonks and S.K. Muthuswamy in Cancer Cell)

2006

Research articles

Bentires-Alj M., Gil SG, Chan R., Wang ZC, Wang Y, Imanaka N, Harris LN, Richardson A, Neel BG and Gu H.
A Role for the Scaffolding Adapter Gab2 in Breast Cancer.
Nature Medicine. 12(1):114-21 (2006)
(Highlight: Nature Reviews Cancer)

Reviews and commentaries

Bentires-Alj M., Kontaridis M. and Neel BG
Stops along the RAS pathway in human genetic disease.
Nature Medicine, 12(3):283-285 (2006)

2004

Research articles

Bentires-Alj M., Paez JG, David FS, Keilhack H, Halmos B, Naoki K, Maris JM, Richardson A, Bardelli A, Sugarbaker DJ, Richards WG, Du J, Girard L, Minna JD, Loh ML, Fisher DE, Velculescu VE, Vogelstein B, Meyerson M, Sellers WR and Neel BG.
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
Cancer Research; 64(24):8816-20 (2004)

Robe PA, Bentires-Alj M., Bonif M, Rogister B, Deprez M, Haddada H, Khac MT, Jolois O, Erkmen K, Merville MP, Black PM, Bours V.
In vitro and in vivo activity of the NF-kB inhibitor sulfasalazine in human glioblastomas.
Clin Cancer Res. 10(16):5595-603 (2004)

Desmet C, Gosset P, Pajak B, Cataldo D, Bentires-Alj M., Lekeux P, Bureau F.
Selective blockade of NF-kB activity in airway immune cells inhibits the effector phase of experimental asthma.
J Immunol. 173(9):5766-75 (2004)

2003

Research articles

 Bentires-Alj M., Barbu, V., Fillet,M., Chariot, A., Relic B., Jacobs, N., Gielen,J., Merville M-P. and Bours V.
NF-kB transcription factor induces drug resistance through MDR1 expression in cancer cells.
Oncogene 9;22(1):90-7 (2003)

Frederich, M., Bentires-Alj M., Tits, M., Angenot, L., Greimers, R., Gielen, J., Bours, V. and Merville M.P.
Isostrychnopentamine, an indolomonoterpenic alkaloid from Strychnos usambarensis, induces cell cycle arrest and apoptosis in human colon cancer cells.
J Pharmacol Exp Ther. 304(3):1103-10 (2003)

Frederich, M., Bentires-Alj M., Tits, M., Angenot, L., Heinen, E., DePauw-Gillet M.C..
Apoptosis induction in human cancer cells by sungucine derivates from Strychnos  icaja root.
Archives of Pharmacology, 367(3):260-5. (2003)

Fillet, M., Bentires-Alj M., Greimers, R., Merville M-P., Piette, J., Bours V and Gielen, J
Ceramide induced cell cycle arrest, necrosis and apoptosis via mitochondria and caspase activation.
Biochemical Pharmacology, 65(10):1633-42 (2003)

Viatour P., Bentires-Alj M., Merville M-P. and Bours V.
NF-kB controls Bcl-2 expression through the P1 and the P2 promoters from the bcl-2 gene.
Leukemia, 17(7):1349-56 (2003)

2002

Baron F., Turhan A., Giron-Michel J., Azzarone B., Bentires-Alj M., Bours V., Bourhis H. J., Chouaib S., Caignard A.
Leukemic target susceptibility to NK cytotoxicity: relationship with BCR-ABL expression.
Blood, 99(6):2107-13. (2002)

Relic B., Bentires-Alj M., Ribbens C., Franchimont N., Guerne P.A., Merville M.P., Bours V. and Malaie M.G.
TNF-α Protects Human Primary Articular Chondrocytes from NO-Induced Apoptosis via NF-kB.
Laboratory Investigation 82(12):1661-72 (2002

2001

Bentires-Alj M., Dejardin E., Viatour P., VanLint C., Froesch B., Reed J., Merville M-P. and Bours V.
Inhibition of the NF-kB transcription factor leads to increased Bax expression in several cancer cell lines.
Oncogene, 17, 20 (22), 2805-2813 (2001)

Chouaib S., Ameyar M., Gay F., Bentires-Alj M., Bours V. and Mami-Chouaib F.
Stable inhibition of NF-kB does not increase tumor cell sensitivity to NK-mediated cytolytic function.
European Journal of Immunology, 31 (2),433-439 (2001)

Bentires-Alj M.,
Nuclear factor kappaB and apoptosis in cancer cells.
Bull Mem Acad R Med Belg, 156(6 Pt 2):329-37 (2001)

2000

Hellin A-C., Bentires-Alj M., Gielen J., Bours V., and Merville M-P.
Roles of NF-kB, p53, and p21/WAF1 in daunomycin-induced cell cycle arrest and apoptosis.
Pharmacol Exp Ther, 295 (3):870-8 (2000)

Bentires-Alj M., Hellin A-C., Lechanteur C., Princen F., Lopes M., Fillet G., Gielen J., Merville M-P. and Bours V.
Cytosine deaminase suicide gene therapy for peritoneal carcinomatosis.
Cancer Gene Therapy, 7,1, 20-26 (2000)

Bours V., Bonnizzi G., Bentires-Alj M., Bureau F., Piette J., Lekeux P. and Merville M.P.
NF-kB activation in response to toxical and therapeutical agents: role in inflammation and cancer treatment.
Toxicology, 153 (1-3): 27-38 (2000)

Bours V., Bentires-Alj M., Hellin AC, Viatour P., Robe P, Delhalle S, Benoit V., and Merville MP
NF-kB, cancer and apoptosis.
Biochemical Pharmacology, 60, 8, 1085-1090 (2000)

1999

Bentires-Alj M., Hellin A-C., Merville M-P. and Bours V.
Stable inhibition of NF-kB in cancer cells does not increase sensitivity to cytotoxic drugs.
Cancer Research 59, 811-815 (1999)

Bentires-Alj M., Merville M-P. and Bours V.
NF-kB and chemoresistance: could NF-kB be an antitumor target?
Drug Resistance Updates , 2, 274-276 (1999)